2023年5月26日,

份额提升了BenchSci利用专有的文本和图像机器学习模型,让科学家能够显著提高的速度和成功的研究在临床前药物发展的任何阶段BenchSci,人工智能解决方案的世界领导者基础生命科学研究和开发(研发),宣布了一项9500万美元(7000万美元)系列D一轮融资由世代投资管理,从现有投资者iNovia资本参与,TCV,黄金投资和f '资本。最近资金带来BenchSci总资金(1.7亿美元)提高到2.18亿美元。“以前,科学家通常不得不花费数百小时理解现有的实验和结论。BenchSci的模型,科学家们可以在几分钟内找到相同的答案,加速药物发现和减少时间和成本来开发潜在拯救生命的药物。”The funds will be used to expand the company’s revolutionary AI drug discovery platform, ASCEND™ by BenchSci, which enables scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early. ASCEND users from BenchSci’s top 10 customers were able to uncover novel targets and disease indications in 22% of key projects and reduced unnecessary experimentation by 40%, contributing to a new era of more efficient, AI-driven drug discovery. “Our focus will always be on what will drive the greatest impact for our customers,” said Liran Belenzon , CEO and Co-Founder of the Canadian-based BenchSci. “Thousands of scientists use our platform every day to move their most promising drug discovery projects forward faster. This investment is validation of the incredible work of our team and the traction we have in the market with the largest pharmaceutical and biotech companies in the world. With the industry 98% failure rate advancing medicines to patients in need, we’re grateful to partner with Generation who shares our thesis that purpose built, innovative AI must be deployed at scale within pharmaceutical R&D to solve the productivity crisis and bring novel medicines to patients years faster.” BenchSci’s ASCEND platform empowers scientists at every stage of preclinical research, regardless of therapeutic area by turning inaccessible, unstructured, and unstandardized experimental evidence from external and internal data sources into actionable insights. Using a proprietary text and image-based machine learning approach, ASCEND decodes and connects the entire available history of biomedical research, combined with customer experimentation and procurement data, to create an unbiased and objective map of the underlying biology of disease. This approach not only helps scientists understand the feasibility of new or existing pursuits but also provides insights on how they can effectively test them and improve translation to clinical trials. This ultimately saves scientists weeks and months of investigation and failed experiment time, expediting the critical scientific conclusions that produce more promising pursuits from the onset. Today, BenchSci’s software is used by 16 of the top 20 pharmaceutical companies and by over 50,000 scientists working at more than 4,500 leading research centers worldwide. “We believe more effective preclinical research is critical to a sustainable healthcare system – drug development is expensive and this cost is only increasing. BenchSci is an example of how AI can support existing drug development by helping scientists focus their research on the most promising areas of science,” said Anthony Woolf, Growth Equity Partner at Generation Investment Management. “Previously, a scientist typically had to spend hundreds of hours to understand existing experiments and conclusions. With BenchSci’s models, scientists can find the same answer in minutes, accelerating drug discovery and reducing the time and cost to develop potentially life-saving drugs.”